Funded in part by Nordea-fonden
Metabolic effects of alternate-day fasting in males with obesity with or without type 2 diabetes
Ingersen A, Helset HR, Calov M, Chabanova E, Harreskov EG, Jensen C, Hansen CN, Prats C, Helge JW, Larsen S, Dela F
Frontiers in physiology · 6 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Controlled clinical trial (classified by our AI screen)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Industry funded
- Company
- Nordea-fonden
- Nonprofit
- Danmarks Frie Forskningsfond
- Grants
- Danmarks Frie Forskningsfond (0602-02606B)
Based on 2 listed funder(s) and full-text disclosure statement.
Publication
- Published
- 2022-11-30 · Front Physiol · vol. 13 · p. 1061063
- Publisher
- Frontiers Media
- Cited
- 13 citations · more than 75% of similar papers · 1.0× the field average
- References
- 55 works
- Access
- Open access (journal) · CC-BY
- Research areas
- Dietary Effects on Health · Diet and metabolism studies · Diet, Metabolism, and Disease
- Keywords
- Type 2 diabetes, Obesity, Medicine, Internal medicine, Endocrinology, Diabetes mellitus, Metabolic syndrome
11 authors
From DK, PL
- Arthur Ingersen · correspondingUniversity of Copenhagen; Frederiksberg Hospital
- Hildegunn Rømma HelsetUniversity of Copenhagen
- Monika CalovUniversity of Copenhagen
- Elizaveta ChabanovaCopenhagen University Hospital
- Eva Gjerlevsen HarreskovUniversity of Copenhagen
- Christina L JensenUniversity of Copenhagen
Abstract
Alternate-day fasting induces oscillations in energy stores. We hypothesized that repeated oscillations increases insulin secretion and sensitivity, and improve metabolic health in patients with obesity with or without type 2 diabetes (T2DM). Twenty-three male patients fasted every other day for 30 h for 6 weeks. Experiments included resting energy expenditure, continuous glucose monitoring, intravenous glucose tolerance test, euglycemic hyperinsulinemic clamp, body composition, hepatic triglyceride content, muscle biopsies which were performed at baseline, during 3 weeks without allowed weight loss, and after additional 3 weeks with weight loss. Bodyweight decreased ∼1% and further ∼3% during weeks one to three and four to six, respectively (p p p p per se. Clinical Trial registration: (ClinicalTrials.gov), (ID NCT02420054).
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.